Health Headlines: Breakthroughs, Setbacks, and Regulatory News from Around the Globe

Recent developments in health include EU's advice on cereulide toxin in infant formula leading to recalls, FDA's rejection of Aquestive's allergy drug, Sanofi's mixed trial results, quarantines due to measles cases in Texas, a pioneering face transplant in Spain, FDA's domestic drug manufacturing boost, and doctors' strike extension in England.

In recent health news, the European food safety body advised a toxin limit on cereulide in infant formula, leading to product recalls by some French companies. This toxin, found in Chinese factory ingredients, has been linked to nausea and vomiting.

The US FDA rejected Aquestive Therapeutics' oral drug for allergic reactions due to packaging issues. The drug, Anaphylm, was aimed at providing an alternative treatment for severe allergic reactions, including anaphylaxis.

In other updates, Sanofi's genetic disorder treatment displayed mixed results, Texas ICE facilities faced quarantines due to measles, and Spain witnessed a pioneering face transplant. Additionally, FDA launched a program to boost US drug manufacturing, and resident doctors in England voted to extend their strike mandate.

(With inputs from agencies.)